THERAPY DOSSIER · th-c82a4a817ebe

TZC01 (thiazolidine hydrochloride), a hybrid compound synthesised from zingerone and cysteamine

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31665488 ↗2019Reported benefit

Protective effects of zingerone derivate on ionizing radiation-induced intestinal injury.

MouseRadiationC57BL/6J (full text); abstract states C57BL/6NMalen = n = 10 per group in each of the two survival experiments (5…Intragastric (oral gavage)50, 100 or 200 mg/kg in the dose ranging survival study; 10…First dose 1 hour before irradiation

Model: Single 12 Gy abdominal X-irradiation (ABI) at a dose rate of 1.2 Gy per min, producing radiation enteritis

TZC01 100 mg/kg gave the best survival benefit, extending mean survival from 4 days in the solvent group (80% mortality) to 5.5 days, and outperformed zingerone or cysteamine alone (4.5 days each). At 3 days after 12 Gy ABI, crypt number was 41.7% higher and villus length 16.39% greater than solven…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…